Effect of melanoma on immune function in the regional lymph node basin

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 654-659

  Negin, Benjamin ^a   Panka, David ^a   Wang, Wei ^a   Siddiqui, Mustaqueem ^a   Tawa, Nicholas ^a   Mullen, John ^a   Tahan, Steven ^a   Mandato, Lucy ^a   Polivy, Adam ^a   Mier, James ^a   Atkins, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOMODULATION; LYMPH NODE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE;

ADULT; AGED; ANTIGENS, CD; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY;

EID: 38949200291     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1577     Document Type: Article

References (29)

1. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997;9:205-13.
2. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-4.
3. Atkins MB, Sosman JA, McDermott DF, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α 2B in patients with metastatic melanoma. Clin Cancer Res 2002;8:3075-81.
4. Kilbridge KL, Kirkwood JM, Haluska FG, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002;20:1311-8.
5. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001;14:604-8.
6. Laing ME, Kay EW, Conlon P, Murphy GM. Malignant melanoma in transplant patients: review of five cases. Clin Exp Dermatol 2006;31:662-4.
7. O'Sullivan GC, Shanahan F, Collins JK. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J Immunol 1996;157:4717-20.
8. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3ζ chain expression by L-arginine. J Biol Chem 2002;277:21123-9.
9. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
10. Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-35.
11. Kono K, Ressing ME, Brandt RM, et al. Decreased expression of signal-transducing ζ chain in peripheral Tcells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996;2:1825-8.
12. Schmielau J, Finn OJ. Suppressed T-cell receptor ζ chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001;7:933-9s.
13. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.
14. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-12.
15. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
16. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005;17:133-44.
17. Dumont N, Arteaga CL. Targeting the TGF β signaling network in human neoplasia. Cancer Cell 2003;3:531-6.
18. Gajewski TF, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40.
19. Adami J, Lindelof B, Ekstrom K, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89:1221-27.
20. Vajdic CM, McCredie MR, van Leeuwen MT, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
21. Clifford GM, Rickenbach M, Dal Maso L, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:407-9.
22. Engels EA, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54.
23. Frisch M, Engels EA, Goedert JJ. AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
24. Liossis SN, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor η chain. J Clin Invest 1998;101:1448-57.
25. Zea AH, Ghosh P, Longo DL, et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 1998;66:499-504.
26. Rabinowich H, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-74.
27. Essner R. Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma. Cancer Metastasis Rev 2006;25:257-67.
28. Munn DH, Lee JR, Jhaver KG, et al. Potential regulatory function of human dendritic cells expressing indolamine 2,3-dioxygenase. Science 2002;297:1867-70.
29. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.